Dr. Amanda Lewis -- Pharmaceutical Payment Report
This page provides a comprehensive transparency report for Dr. Amanda Lewis, a Rheumatology physician based in Princeton, NJ. All payment data is sourced from the CMS Open Payments (Sunshine Act) database. Dr. Amanda Lewis has received $17,477.54 in total pharmaceutical industry payments across 1 transactions from 1 pharmaceutical companies.
Physician Profile
The following profile information is sourced from the National Provider Identifier (NPI) registry and CMS Open Payments records.
- Full Name: Dr. Amanda Lewis
- Medical Specialty: Rheumatology
- Practice Location: Princeton, NJ, New Jersey
- NPI Number: 1805241670
- Transparency Score: 50/100
- Payment Records Span: 2025-09-12 to 2025-09-12
Payment Summary
Dr. Amanda Lewis has received a total of $17,477.54 in pharmaceutical industry payments across 1 recorded transactions in the CMS Open Payments database. The average payment amount is $17,477.54 per transaction.
- Total Payments Received: $17,477.54
- Number of Transactions: 1
- Average Payment: $17,477.54
- Transparency Score: 50/100 -- This score reflects the overall payment profile relative to peers in Rheumatology. A higher score indicates fewer or more routine payments.
- Number of Pharma Relationships: 1 pharmaceutical companies
- Drugs/Devices Referenced: 1 distinct products
Payment Breakdown by Category
The following table shows how Dr. Amanda Lewis's pharmaceutical payments break down by payment category. Understanding the mix of payment types provides important context about the nature of the doctor-pharma relationship.
| Payment Category | Amount | Description |
|---|---|---|
| Consulting Fees | $17,477.54 | Advisory board participation, clinical consulting, and expert opinion services |
The largest payment category for Dr. Amanda Lewis is Consulting Fees, accounting for 100% ($17,477.54) of total pharmaceutical payments received. This suggests active involvement in pharmaceutical company advisory and educational programs.
Pharmaceutical Company Relationships
The following pharmaceutical and medical device companies have made payments to Dr. Amanda Lewis. Click on any company name to view their full physician payment profile and spending patterns.
| Company | Total Paid | Transactions |
|---|---|---|
| AbbVie Inc | $17,477.54 | 1 |
Dr. Amanda Lewis has a financial relationship with AbbVie Inc, receiving $17,477.54 in total. Having a single pharmaceutical company relationship means all payments come from one source, which may indicate a focused consulting or research relationship.
Drugs and Medical Devices Referenced in Payments
The following drugs and medical devices have been referenced in pharmaceutical payments to Dr. Amanda Lewis. These references indicate that the payment was related to the marketing, consulting, or clinical use of these products.
- Trulicity -- Referenced in payment records from pharmaceutical companies to Dr. Amanda Lewis
The presence of a drug or device in a payment record means the pharmaceutical company associated the payment with that product. This is common for consulting fees related to a specific medication, speaking engagements about a product, or research involving a particular drug or device.
AI Transparency Analysis
The following analysis was generated by artificial intelligence based on Dr. Amanda Lewis's payment history, specialty peer comparisons, and payment pattern analysis. This analysis is not medical or legal advice.
Dr. Amanda Lewis, a Rheumatologist in Princeton, NJ, has a pharmaceutical payment profile characterized by a single, substantial payment. With a total of $17,477.54 from pharmaceutical companies, this amount is derived from one transaction. This single payment is from AbbVie Inc., totaling the entire reported amount. The payment is designated for consulting services and is scheduled for September 12, 2025. Comparing Dr. Lewis's payment volume to her peers in Rheumatology reveals a profile that is significantly different from the norm. While many rheumatologists engage in various forms of professional interaction with pharmaceutical companies, resulting in a range of payment types and volumes, Dr. Lewis's profile is dominated by this one large consulting fee. The average rheumatologist may receive multiple payments throughout the year for activities such as speaking engagements, advisory boards, research, and educational events. The total volume for an average rheumatologist can vary widely, but a single payment of this magnitude, especially for consulting, stands out. The concentration of the entire payment from AbbVie Inc. suggests a specific, potentially ongoing, professional relationship. AbbVie is a major pharmaceutical company with significant products in the rheumatology space, including treatments for rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. A large consulting fee from a company with such a strong presence in the specialty could indicate Dr. Lewis's expertise is being sought for product development, strategic advice, or market insights related to these conditions. The payment type breakdown is straightforward in this case: 100% consulting. There are no reported payments for speaking, research, meals, travel, or ownership interests. This singular focus on consulting, as opposed to a mix of activities, is noteworthy. It suggests a direct engagement where Dr. Lewis's specialized knowledge is being compensated. Whether this pattern warrants closer attention depends on the nature of the consulting. A single, large consulting payment, especially when scheduled for the future, could represent a legitimate engagement for providing expert advice. However, it is crucial to consider the potential for influence. The rheumatology field relies heavily on biologic and synthetic disease-modifying antirheumatic drugs (DMARDs), many of which are developed and marketed by large pharmaceutical companies like AbbVie. When a physician receives significant compensation from a company whose products they prescribe, it raises questions about potential bias, even if unintentional. For patient care, these payments mean that Dr. Lewis's clinical decisions, particularly regarding medication choices, could be influenced by her relationship with AbbVie. While the payment is for consulting, the knowledge gained or the relationship fostered might subtly shape her perspective on treatment options. Patients should be aware that their doctor's prescribing patterns might be influenced by financial ties to pharmaceutical companies. Transparency about these relationships is key to maintaining trust and ensuring that treatment decisions are solely based on the patient's best interests and evidence-based medicine. Patients should feel empowered to discuss any concerns about their doctor's relationships with pharmaceutical companies and explore all available treatment options.
Patient Guidance: Questions to Ask Your Doctor
If Dr. Amanda Lewis is your physician, here is practical guidance on how to understand and discuss pharmaceutical industry relationships:
When considering your doctor's relationship with pharmaceutical companies, it's important to maintain a balanced perspective. Many physicians engage in legitimate professional activities with drug manufacturers, such as consulting or participating in advisory boards, which can contribute to the development of new treatments and provide valuable insights. However, it's also crucial to be aware of potential influences. At your next appointment, consider asking your doctor about their relationships with pharmaceutical companies. You might inquire, "Do you receive any payments or compensation from drug companies whose medications you prescribe?" or "How do you decide which medications are best for your patients, especially when there are multiple options from different companies?" Red flags to watch for include a doctor who exclusively prescribes medications from a company they receive significant payments from, or if they seem overly dismissive of alternative treatments or generic options. It's normal for doctors to have relationships with pharma companies, especially in specialized fields like rheumatology where innovation is constant. However, when these relationships involve large sums of money or a lack of transparency, it warrants closer attention. Evaluate your doctor's prescribing patterns by looking for consistency with evidence-based guidelines and considering whether they offer a range of treatment options. If you have concerns, discuss them openly with your doctor. If you remain uncomfortable, seeking a second opinion or consulting with another specialist might be a reasonable step.
Peer Comparison: How Dr. Amanda Lewis Compares to Other Rheumatology Physicians
Dr. Lewis's total payment volume of $17,477.54 from a single transaction is unusual when compared to the average rheumatologist. While many rheumatologists receive multiple, smaller payments for various activities like speaking, research, and consulting throughout the year, Dr. Lewis's profile is dominated by one large future consulting fee. The average payment volume for rheumatologists can vary significantly, but this singular, substantial payment from AbbVie Inc. places her outside the typical pattern of distributed professional engagement.
Recent Payment Records
The following table shows the most recent pharmaceutical industry payments recorded for Dr. Amanda Lewis in the CMS Open Payments database. Click on any payment to view the full report.
| Company | Amount | Type | Drug/Device | Date | Conflict Level |
|---|---|---|---|---|---|
| AbbVie Inc | $17,477.54 | consulting | Trulicity | 2025-09-12 | Not Assessed |
Frequently Asked Questions About Dr. Amanda Lewis's Pharma Payments
Below are common questions patients ask about physician pharmaceutical payment data.
Is Dr. Amanda Lewis taking too much pharma money?
Dr. Lewis has one reported payment of $17,477.54 from AbbVie Inc. for consulting, scheduled for the future. While this is a substantial amount from a single source, it represents a single professional engagement rather than a broad pattern of numerous payments. Compared to the average rheumatologist who might receive multiple smaller payments, this profile is distinct. Whether it's 'too much' is subjective, but it warrants awareness of the potential for influence given AbbVie's role in rheumatology medications. Transparency is key, and this single large payment should be viewed in the context of her overall practice and patient care.
What pharma companies pay Dr. Amanda Lewis?
Dr. Amanda Lewis receives payments exclusively from AbbVie Inc. The total amount reported is $17,477.54, which is designated for consulting services and is scheduled for September 12, 2025.
Should I switch doctors because of pharma payments?
Switching doctors solely based on pharmaceutical payments is a significant decision. It's more productive to first understand the nature and extent of these payments. If your doctor has a pattern of receiving large sums from a single company, especially for activities like consulting or speaking, it's reasonable to inquire about how this influences their prescribing decisions. Red flags include a lack of transparency, a tendency to prescribe only medications from companies they are affiliated with, or dismissiveness towards alternative treatments. If you have open discussions with your doctor and remain uncomfortable or unconvinced that your best interests are the sole priority, then seeking a second opinion or a new physician might be appropriate.
What kinds of payments does this doctor receive?
Dr. Lewis receives payments solely for consulting services. The total amount reported is $17,477.54 from AbbVie Inc., scheduled for 2025. There are no reported payments for speaking, research, meals, travel, or ownership interests in her profile.
How do these payments compare to other Rheumatology?
Dr. Lewis's payment profile, with a single $17,477.54 consulting fee from AbbVie Inc., is atypical for Rheumatology. While many rheumatologists receive multiple, smaller payments for various professional activities, her profile is dominated by this one substantial future payment. The average rheumatologist may have a more diversified stream of income from pharmaceutical interactions, making Dr. Lewis's singular large engagement stand out.
Do pharma payments affect prescribing quality?
Research suggests that even small payments from pharmaceutical companies can influence physician prescribing behavior, potentially leading to increased prescription of the paying company's drugs. While payments for consulting, speaking, or research are intended to compensate for expertise and contributions, they can create unconscious bias. The quality of care is not necessarily diminished, but the choice of medication might be influenced. It is crucial for physicians to maintain awareness of this potential bias and prioritize evidence-based medicine and patient-specific needs above all else.
How can I verify this payment data?
You can verify this payment data directly through the Centers for Medicare & Medicaid Services (CMS) Open Payments database. This publicly accessible website allows you to search for physicians by name or National Provider Identifier (NPI). The database details payments made by pharmaceutical and medical device companies to physicians and teaching hospitals, including the paying company, the physician, the amount, and the nature of the payment. Dr. Lewis's NPI is 1805241670, which you can use to find her specific records on the CMS Open Payments website.
Understanding This Doctor Payment Report
This transparency report for Dr. Amanda Lewis is based on data from the CMS Open Payments database, which is maintained by the Centers for Medicare and Medicaid Services under the Physician Payments Sunshine Act. Here are important things to understand:
- Payment does not imply wrongdoing. Many pharmaceutical payments represent legitimate professional activities such as consulting on drug development, speaking at medical education events, and conducting clinical research.
- Context matters. A large payment for conducting a clinical trial has very different implications than a large payment for promotional speaking. The payment breakdown by category above provides this context.
- Peer comparison is important. Whether a payment amount is unusual depends heavily on the physician's specialty, geographic location, and career stage. Rheumatology physicians may have very different payment norms than physicians in other fields.
- Data may be incomplete. The CMS Open Payments database captures payments from pharmaceutical and medical device manufacturers. It does not include payments from other sources, such as hospitals, insurance companies, or government agencies.
- Reporting thresholds apply. Small payments below certain thresholds may not be individually reported. The totals reflect payments above reporting minimums set by CMS regulations.
About the Physician Payments Sunshine Act
The Physician Payments Sunshine Act, enacted as Section 6002 of the Affordable Care Act in 2010, requires pharmaceutical and medical device companies to report payments and other transfers of value to physicians and teaching hospitals to CMS. This law was designed to increase transparency in the financial relationships between the healthcare industry and medical providers.
Under this law, Dr. Amanda Lewis's pharmaceutical payments are publicly disclosed. The types of reportable transactions include consulting fees, compensated speaking or educational activities, honoraria, gifts, entertainment, food and beverages, travel and lodging, education or conference attendance, research grants, charitable contributions, royalties or licenses, current or prospective ownership interests, and direct compensation for services other than consulting.
The Open Payments data for Dr. Amanda Lewis and all other physicians can be accessed at the official CMS Open Payments website.
Related Resources
- Rheumatology Specialty Payment Data -- See payment patterns for all rheumatology physicians
- New Jersey Physician Payments -- Browse pharmaceutical payments to physicians in New Jersey
- Rheumatology Physicians in New Jersey -- Compare Dr. Amanda Lewis to peers in the same state and specialty
- AbbVie Inc Payment Profile -- View all payments made by Dr. Amanda Lewis's largest pharmaceutical partner
- Search for Another Doctor or Company -- Look up any physician or pharmaceutical company in our database
- Official CMS Open Payments Database -- Verify payment data directly with the federal government
- NPI Registry -- Look up Dr. Amanda Lewis's NPI (1805241670) in the official provider registry
Data from CMS Open Payments (Sunshine Act). Payment does not imply wrongdoing. AI analysis is not medical or legal advice. Consult your healthcare provider about any concerns.